Company: OCEA
Filing Date: 2025-02-26
Form Type: DEF 14A
Source: 0001493152-25-008279
Chunk: 2

Company: Ocean Biomedical, Inc.
Filing Date: 2025-02-26
Form: DEF 14A
Chunk 2
---
 may consider important in determining how to vote your shares at the Annual Meeting.

At the Annual Meeting, we will ask stockholders to (i) authorize the slate of directors, (ii) authorize a reverse split of our common stock of 1:2 to 1:250, (iii) authorize a new Company Incentive Plan; (iv) ratify the appointment of Berkowitz Pollack Brant, CPAs as the Company’s independent registered public accounting firm for the year ended December 31, 2024; (v) the approval, on a non-binding advisory basis, of the frequency of future stockholder advisory votes to approve the compensation of our named executive officers; and (vi) non-binding advisory vote on approval of compensation of our named executive officers.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON MARCH 28, 2025:

Our official Notice of Annual Meeting of Stockholders and Proxy Statement

are available at:

https://www.cstproxy.com/oceanbiomedical/2025

| 1 |

The U.S. Securities and Exchange Commission’s (the “ SEC”) “Notice and Access” rule provides that companies must include in their mailed proxy materials instructions as to how stockholders can access our proxy statement and other soliciting materials on the Internet, a listing of matters to be considered at the relevant stockholder meeting, and instructions as to how shares can be voted. Since we are mailing full sets of proxy materials for the Annual Meeting to our stockholders, as permitted by SEC proxy rules, we are including the information required by the Notice and Access rule in this proxy statement and in the accompanying Notice of Annual Meeting of Stockholders and proxy card, and we are not distributing a separate Notice of Internet Availability of Proxy Materials.

What Are You Voting On?

You will be asked to vote on the following proposals at the Annual Meeting:

At the Annual Meeting, we will ask stockholders to (i) authorize the slate of directors, (ii) authorize a reverse split of our common stock of 1:2 to 1:250, (iii) authorize a new Company Incentive Plan; (iv) ratify the appointment of Berkowitz Pollack Brant, CPAs as the Company’s independent registered public accounting firm for the year ended December 31, 2024; (v) the approval, on a non-binding advisory basis, of the frequency of future stockholder advisory votes to approve the compensation of our